BREAKING
Encompass Health Corporation reports Q4 2025 results, issues 2026 guidance 11 hours ago Graham Corporation Expands Capabilities Across Defense, Energy, and Space Markets 11 hours ago Graham Corporation Sees Robust Q3 on Defense Momentum and FlackTek Integration 11 hours ago Biogen’s Q4 FY25 adj. earnings decline, but beat estimates; revenue down 7% 12 hours ago Infographic: How Philip Morris (PM) performed in Q4 2025 financial results 12 hours ago Abbott reports positive results from study on its atrial fibrillation therapies 13 hours ago Atmus Welcomes Heath Sharp to Board of Directors 15 hours ago Cboe Global Markets Q4 2025 adj. earnings jump on record high revenues 15 hours ago Zurn Elkay beats fourth quarter estimates, forecasts growth for 2026 3 days ago Yum China Reports Fourth Quarter and Full Year 2025 Financial Results 3 days ago Encompass Health Corporation reports Q4 2025 results, issues 2026 guidance 11 hours ago Graham Corporation Expands Capabilities Across Defense, Energy, and Space Markets 11 hours ago Graham Corporation Sees Robust Q3 on Defense Momentum and FlackTek Integration 11 hours ago Biogen’s Q4 FY25 adj. earnings decline, but beat estimates; revenue down 7% 12 hours ago Infographic: How Philip Morris (PM) performed in Q4 2025 financial results 12 hours ago Abbott reports positive results from study on its atrial fibrillation therapies 13 hours ago Atmus Welcomes Heath Sharp to Board of Directors 15 hours ago Cboe Global Markets Q4 2025 adj. earnings jump on record high revenues 15 hours ago Zurn Elkay beats fourth quarter estimates, forecasts growth for 2026 3 days ago Yum China Reports Fourth Quarter and Full Year 2025 Financial Results 3 days ago
ADVERTISEMENT
Analysis

Tilray earnings preview: Investors need more than just production expansion

Though the marijuana industry has been seeing overall tremendous growth, one prominent name has been pulling it down – Tilray (NASDAQ: TLRY). Even as other pot stocks gained considerably since the beginning of this year, Tilray has plunged over 36%, much to the annoyance of investors. The Canadian marijuana firm is slated to report first-quarter […]

May 11, 2019 2 min read

Though the marijuana industry has been seeing overall tremendous growth, one prominent name has been pulling it down – Tilray (NASDAQ: TLRY). Even as other pot stocks gained considerably since the beginning of this year, Tilray has plunged over 36%, much to the annoyance of investors.

The Canadian marijuana firm is slated to report first-quarter earnings results on May 14, Tuesday after the market closes. Analysts are expecting another quarterly loss, this time of 25 cents per share, as the company continues to invest heavily on production expansion. Revenues are estimated to be $21.6 million, compared to $15.5 million it reported in the prior sequential quarter.

Reports of production ramps have already been priced into the stock, which is still struggling to reverse its downward trajectory. Despite the ramps, Tilray continues to underperform when compared to peers such as Canopy Growth (NYSE:CGC) and Aurora Cannabis (NYSE: ACB).

Cannabis Stocks- Performance Comparison

Investors are also concerned over Tilray’s inability to turn profitable, despite some of its peers starting to make money. During the last reported quarter, the company had reported a net loss of $31 million, or $0.33 per share, wider than the previous year’s loss of $3 million, or $0.04 per share.

ADVERTISEMENT

The big beverage partnership

The partnership with Budweiser-parent Anheuser Busch Inbev (NYSE: BUD) to produce cannabis-based beverages had been touted as the biggest USP of Tilray going forward. However, Wall Street has started losing interest in this following reports that Anheuser’s lack of materialistic commitment towards this project.

Meanwhile, New Age Beverages Corporation (NASDAQ: NBEV) has made considerable headway in this regard, by inking a deal to develop and distribute Marley branded cannabis-infused beverages.

READ: THE QUESTION EVERY POT INVESTOR ASKS HIMSELF – AURORA CANNABIS OR HEXO?

Tilray has made other promising partnerships as well, including ones with Novartis (NYSE: NVS) and Authentic Brands Group. But its high time the partnerships start showing up benefits in the balance sheet as well.

ADVERTISEMENT

Consecutive bearish comments from analysts and estimate revisions have hurt the confidence of investors in the stock, at least for the short-term.

Tilray management has a mammoth job of convincing people to stay invested as it heads to the conference call on Tuesday. The company is likely to focus on its long-term prospects and path to profitability.

 

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

ADVERTISEMENT